Hu7691

Hu7691 is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice[1].

Product Specifications

CAS Number

[2360523-76-6]

UNSPSC

12352005

Target

Akt; PKA; PKC; Ribosomal S6 Kinase (RSK) ; ROCK; SGK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hu7691.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N[C@@H]1CNCC[C@H]1C2=CC=C(F)C(F)=C2)C3=CC=C(C4=CC=NN4C)C=C3F.[H]Cl

Molecular Formula

C22H22ClF3N4O

Molecular Weight

450.88

References & Citations

[1]Jinxin Che, et al. Discovery of N- ((3 S,4 S) -4- (3,4-Difluorophenyl) piperidin-3-yl) -2-fluoro-4- (1-methyl-1 H-pyrazol-5-yl) benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. J Med Chem. 2021 Aug 26;64 (16) :12163-12180.